In many trials, such as EMPA-REG outcomes [13], EMPULSE [29] or EMPAG-HF [30], a significant improvement in clinical congestion was evident, supporting the hypothesis that a reduction in the ECW volume is a key component in the clinical benefits of SGLT-2 inhibitors. Here, SLC5A2 is linked to hydrops fetalis.